[Clinical efficacy of Auricularum compared with its bacteriologic efficacy in vitro].
We compared the clinical efficacy of Auricularum to its bacteriological efficacy in 36 patients with a chronic middle ear disease. The clinical study confirms the very good efficacy of Auricularum with an improvement rate equal to 81% and 69.4% of "very good" results. The bacteriological study confirms the usual sensitivity of gram-negative bacilli (except the Proteus) to polymyxine B, the sensitivity of gram-positive germs to tetracycline for 60% of them and the sensitivity of fungus (isolated only once) to nystatine. Moreover, the bacteriological study shows that Auricularum with a concentration more or equal to 0.1 ml inhibits every germ, including the well-known resistant germs. This concentration of 0.1 ml corresponds to 2 drops of the drug in suspension and is less than the recommended dosage. This finding proves the very good efficacy of Auricularum in chronic middle ear diseases, including the ones due to usual resistant germs to the two antibiotics (polymyxine B and oxytetracycline) enclosed in the drug composition.
Frèche
C
C
Chef de Service ORL, Expert clinicien spécialisé, Hôpital Foch, Suresnes.
Acar
J F
JF
D001431:Bacteriological Techniques; D002908:Chronic Disease; D003907:Dexamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D008826:Microbial Sensitivity Tests; D009761:Nystatin / Q000627:therapeutic use*; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology; D010118:Oxytetracycline / Q000627:therapeutic use*; D011112:Polymyxin B / Q000627:therapeutic use*; D011113:Polymyxins / Q000627:therapeutic use*
D004338:Drug Combinations; D011113:Polymyxins; C059464:auricularum; D009761:Nystatin; D003907:Dexamethasone; D011112:Polymyxin B; D010118:Oxytetracycline
Efficacité clinique d'auricularum comparée à son efficacité bactériologique in vitro.